369.20
0.22%
Axis Direct
The company's capital allocation is on two fronts - R&D and the acquisition of Viatris.This has resulted in returns ratios falling below ~10% despite growth in the business. A huge looming net debt of $1.2 Bn could lead to further stake dilution in Biocon biologics. Recommendation: HOLD
Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.
More from Biocon Ltd.
Recommended